Research progress of abnormal lipid metabolism and its intervention in diffuse large B-cell lymphoma

doi:10.3760/cma.j.cn441417-20240101-04007

Abstract

Abstract:

Abnormal lipid metabolism is an important metabolic change in the occurrence and development of malignant tumors. Lipid reprogramming caused by changes in lipid metabolism-related genes and subsequent abnormal lipid metabolites have important effects on the proliferation, invasion, and metastasis of tumor cells. Clinical and basic studies have shown that there are abnormal expressions of lipid metabolism-related genes and metabolites in patients with diffuse large B-cell lymphoma (DLBCL), and these changes are related to prognosis. Intervention targeting abnormal lipid metabolism can change the biological behaviors of DLBCL cells. Therefore, this article reviews the abnormal lipid metabolism in DLBCL, its mechanism, and the intervention targeting lipid metabolism, so as to provide a useful summary for exploring the potential diagnosis and treatment targets of DLBCL.

Key words:

Diffuse large B-cell lymphoma, Lipid metabolism, Mechanism, Intervention, Progress

摘要：

脂质代谢异常是恶性肿瘤发生发展中重要的代谢改变。脂质代谢相关基因变化引发的脂质重编程及后续脂质代谢产物异常对于肿瘤细胞的增殖、侵袭和转移具有重要影响。临床与基础研究显示，弥漫大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）患者中存在着脂质代谢相关基因及代谢产物的异常表达，且该变化与预后有关；靶向脂质代谢异常的干预可以改变DLBCL细胞生物学行为。因此，本文对DLBCL中存在的脂质代谢异常及其发生机制和靶向脂质代谢的干预进行综述，为挖掘DLBCL的潜在诊治靶点提供有益总结。

关键词:

弥漫大B细胞淋巴瘤, 脂质代谢, 机制, 干预, 进展

Hong Jinquan, Huang Xiaoling, Huang Zhenyu, Huang Haobo.

Research progress of abnormal lipid metabolism and its intervention in diffuse large B-cell lymphoma [J]. International Medicine and Health Guidance News, 2025, 31(4): 559-562.

洪金全黄晓玲黄震宇黄豪博.

弥漫大B细胞淋巴瘤中脂质代谢异常及其干预的研究进展 [J]. 国际医药卫生导报, 2025, 31(4): 559-562.

References

[1] Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment[J]. Am J Hematol, 2019,94(5):604-616. DOI: 10.1002/ajh.25460.
[2] Ayers EC, Li S, Medeiros LJ, et al. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure[J]. Cancer, 2020,126(2):293-303. DOI: 10.1002/cncr.32526.
[3] Long J, Zhang CJ, Zhu N, et al. Lipid metabolism and carcinogenesis, cancer development[J]. Am J Cancer Res,2018,8(5):778-791.
[4] 蔡艺威,闫晨名,岳林皓,等. 脂质代谢在乳腺癌进展过程中的重要作用与机制[J]. 国际医药卫生导报,2024,30(15):2470-2473. DOI:10.3760/cma.j.issn.1007-1245.2024. 15.002.
[5] Liebisch G, Fahy E, Aoki J, et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures[J]. J Lipid Res,2020,61(12):1539-1555. DOI: 10.1194/jlr.S120001025.
[6] Fan L, Lin Q, Huang X, et al. Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis[J]. BMC Cancer, 2021,21(1):1255. DOI: 10.1186/s12885-021-08963-6.
[7] Huang X, Wang Y, Huang Z, et al. Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study[J]. BMC Cancer, 2024,24(1):62. DOI: 10.1186/s12885-024-11818-5.
[8] Gao R, Liang JH, Wang L, et al. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma[J]. Int J Cancer, 2018,143(8):1884-1895. DOI: 10.1002/ijc.31590.
[9] Wang F, Lu L, Chen H, et al. Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab[J]. Ann Hematol, 2023,102(2):393-402. DOI: 10.1007/s00277- 023-05092-x.
[10] Li W, Gao M, Xue W, et al. Palmitic acid reduces the methylation of the FOXO1 promoter to suppress the development of diffuse large B-cell lymphoma via modulating the miR-429/DNMT3A axis[J]. Chin J Nat Med, 2024,22(6):554-567. DOI: 10.1016/S1875-5364(24)60655-2.
[11] Pera B, Krumsiek J, Assouline SE, et al. Metabolomic profiling reveals cellular reprogramming of B-cell lymphoma by a lysine deacetylase inhibitor through the choline pathway[J]. EBioMedicine, 2018,28:80-89. DOI: 10.1016/j.ebiom.2018.01.014.
[12] Koresawa R, Yamazaki K, Oka D, et al. Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma[J]. Br J Haematol, 2016,174(2):264-274. DOI: 10.1111/bjh. 14054.
[13] Lupino L, Perry T, Margielewska S, et al. Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma[J]. Leukemia, 2019,33(12):2884-2897. DOI: 10.1038/s41375-019-0478-9.
[14] Uddin S, Hussain AR, Ahmed M, et al. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma[J]. Mol Cancer Ther, 2010,9(5):1244-55. DOI: 10.1158/1535-7163.MCT-09-1061.
[15] Kapadia B, Nanaji NM, Bhalla K, et al. Fatty acid synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL[J]. Nat Commun, 2018,9(1):829. DOI: 10.1038/s41467-018-03028-y.
[16] Gifford GK, Gifford AJ, Chen Q, et al. Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2020,61(8):1810-1822. DOI: 10.1080/10428194.2020.1742899.
[17] 段素素,雷娜,吴海妹,等. 脂质代谢调控机制及相应药物研究进展[J]. 山东医药,2021,61(20):93-96. DOI:10.3969/j.issn.1002-266X.2021.20.024.
[18] Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer[J]. Cell Metab, 2020,31(1):62-76. DOI: 10.1016/j.cmet.2019.11.010.
[19] Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas[J]. Cancer Cell, 2013,23(6):826-838. DOI: 10.1016/j.ccr.2013.05.002.
[20] Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20[J]. PLoS Med, 2008,5(3):e64. DOI: 10.1371/journal.pmed.0050064.
[21] Song MK, Chung JS, Lee GW, et al. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era[J]. Leuk Res, 2015,39(2):211-215. DOI: 10.1016/j.leukres.2014.12.003.
[22] Smyth L, Blunt DN, Gatov E, et al. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects[J]. Br J Haematol, 2020,191(3):396-404. DOI: 10.1111/bjh. 16635.
[23] Ennishi D, Asai H, Maeda Y, et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy[J]. Ann Oncol, 2010,21(6):1217-1221. DOI: 10.1093/annonc/mdp490.
[24] Hohaus S, Tisi MC, Bellesi S, et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy[J]. Cancer Med, 2018,7(1):270-281. DOI: 10.1002/cam4.1166.
[25] Bittenbring JT, Neumann F, Altmann B, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab[J]. J Clin Oncol, 2014 ,32(29):3242-3248. DOI: 10.1200/JCO.2013.53.4537.
[26] Han J, Tang Y, Zhong M, et al. Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line[J]. Mol Med Rep, 2019,20(6):5064-5074. DOI: 10.3892/mmr.2019.10756.